[1] Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis, 1986, 8: 283-98.
[2] Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med, 1999, 107(5): 450-455.
[3] Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019, 69(6): 2672-2682.
[4] 中华医学会肝病学分会脂肪肝和酒精肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018,21(2): 177-186.
[5] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol, 2017, 67(4): 862-873.
[6] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. doi: 10.1097/HEP.0000000000000323.
[7] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73(1): 202-209.
[8] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67(1): 328-357.
[9] Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?Hepatology, 2022, 76(5): 1423-1437.
[10] Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. Liver Int, 2022, 42(2): 277-287.
[11] Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 2017, 65(5): 1557-1565.
[12] van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep, 2021, 3(5): 100350.
[13] Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol, 2021, 75(6): 1284-1291.
[14] Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. Hepatobiliary Pancreat Dis Int,2022,21(2):154-161.
[15] Sarin SK, Eslam M, Fan JG, et al. MAFLD, patient-centred care, and APASL. Hepatol Int,2022,16(5):1032-1034.
[16] George J, Lau G, Kawaguchi T, et al. Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN). Hepatol Int, 2023,17(3):546-549. |
